{"analyses":[{"ciLowerLimit":"0.386","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.779","groupDescription":"Anetumab ravtansine versus vinorelbine","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.313747","paramType":"Hazard Ratio (HR)","paramValue":"0.829","statisticalComment":"one-sided log-rank test stratified by time to progression (TTP) on first line treatment","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"value cannot be estimated due to censored data","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"value cannot be estimated due to censored data","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"Time to worsening of symptoms characteristic of mesothelioma (TTWS) was defined in patients evaluable for assessing worsening of symptoms, as the time from randomization until the first worsening of symptoms characteristic of mesothelioma. Patients who died, were lost to follow-up, or ended (MD Anderson Symptom Inventory-Malignant Pleural Mesothelioma) MDASI-MPM assessments without confirmed worsening of symptoms were censored at the date of their last MDASI-MPM assessment with a non-missing (Composite Symptom Score) CSS.","dispersionType":"95% Confidence Interval","groups":[{"description":"Test drug: 6.5 mg/kg every 3 weeks; Intravenous (IV) infusion over 1 hour","id":"OG000","title":"Anetumab Ravtansine"},{"description":"Active comparator: 30 mg/m\\^2 once weekly","id":"OG001","title":"Vinorelbine"}],"paramType":"MEDIAN","populationDescription":"The secondary efficacy analysis was performed in the ITT (Intent-to-treat) analysis set.","reportingStatus":"POSTED","timeFrame":"up to approx. 30 months (data cut-off: 31-May-2017)","title":"Time to Worsening of Symptoms Characteristic of Mesothelioma","type":"SECONDARY","unitOfMeasure":"days"}